In type-2 diabetics with abdominal obesity, hyperfiltration is a risk factor for accelerated GFR decline and nephropathy. In this academic, single-center, parallel-group, Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial (ClinicalTRials.gov number: NCT01213212), consenting >18-year

1 IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Centro di Ricerche Cliniche per le Malattie Rare “Aldo e Cele Daccò”, Bergamo, Italy; 2 Unit of Nephrology, Azienda Socio Sanitaria Territoriale (ASST) Ospedale Papa Giovanni XXIII, Bergamo, Italy; 3 Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; 4 Department of Clinical and Experimental Sciences, Brescia University Medical School, Brescia, Italy; 5 Department of Medicine, Washington University in St. Louis, MO, USA; 6 CEINGE Biotecnologie Avanzate, Napoli, Italy